stoxline Quote Chart Rank Option Currency Glossary
  
Agios Pharmaceuticals, Inc. (AGIO)
38.26  0.26 (0.68%)    05-30 14:01
Open: 38.33
High: 38.5325
Volume: 266,503
  
Pre. Close: 38
Low: 37.23
Market Cap: 2,172(M)
Technical analysis
2024-05-30 1:41:21 PM
Short term     
Mid term     
Targets 6-month :  46.36 1-year :  54.15
Resists First :  39.7 Second :  46.36
Pivot price 34.53
Supports First :  34.32 Second :  31
MAs MA(5) :  35.87 MA(20) :  34.28
MA(100) :  29.16 MA(250) :  26.49
MACD MACD :  1.3 Signal :  1
%K %D K(14,3) :  85 D(3) :  62.4
RSI RSI(14): 66.9
52-week High :  39.7 Low :  19.79
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ AGIO ] has closed below upper band by 4.7%. Bollinger Bands are 66.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 39.68 - 39.9 39.9 - 40.08
Low: 36.81 - 37.11 37.11 - 37.36
Close: 37.55 - 38 38 - 38.37
Company Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Headline News

Thu, 30 May 2024
Agios Pharmaceuticals (NASDAQ:AGIO) Reaches New 12-Month High at $39.70 - Defense World

Thu, 30 May 2024
Teacher Retirement System of Texas Sells 2876 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World

Wed, 29 May 2024
Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty - Zacks Investment Research

Wed, 29 May 2024
54,541 Shares in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Purchased by Trexquant Investment LP - MarketBeat

Wed, 29 May 2024
Trexquant Investment LP Acquires Shares of 54541 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World

Tue, 28 May 2024
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday? - Agios Pharmaceuticals (NASDAQ:AGIO) - Benzinga

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 57 (M)
Held by Insiders 4.826e+007 (%)
Held by Institutions 1.4 (%)
Shares Short 6,600 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.8676e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 124.3 %
Return on Equity (ttm) -24.6 %
Qtrly Rev. Growth 2.94e+007 %
Gross Profit (p.s.) 56.79
Sales Per Share -48.91
EBITDA (p.s.) 0
Qtrly Earnings Growth -6.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -301 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -0.2
Price to Book value 0
Price to Sales -0.79
Price to Cash Flow 2.37
Stock Dividends
Dividend 0
Forward Dividend 6.51e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android